A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2019
Price : $35 *
At a glance
- Drugs Asciminib (Primary) ; Imatinib (Primary) ; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ASC4MORE
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Nov 2019 Planned End Date changed from 3 Mar 2022 to 13 Jun 2022.
- 10 Nov 2019 Planned primary completion date changed from 12 Mar 2021 to 22 Jun 2021.
- 27 Aug 2019 Planned End Date changed from 20 Oct 2021 to 3 Mar 2022.